Consumer Commission Fines BigMuscles Nutrition For Misleading Health Claims

Mumbai: The consumer commission in Mumbai has deemed BigMuscles Nutrition guilty of service deficiency for using ‘unknown’ amino acids to boost protein content in one of its health supplements. This practice, known as protein-spiking, has raised serious health concerns.

The District Consumer Disputes Redressal Commission’s July 15 order stated that consumption of such products posed health risks, ranging from short-term side effects like headaches and nausea to long-term issues like liver damage and heart problems.

BigMuscles Nutrition was ordered to pay Rs 36,409 to the complainant for the product cost and lab testing. The commission also criticized the company for making false claims about their product and continuing misleading practices.

Related Posts

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus board approved a buyback of up to Rs 1100 crore at Rs 1,150 per share, along with a 100 percent dividend for FY26. Zydus Lifesciences reported a rise in…

Chemists strike on May 20: Reasons behind today’s all-India strike

While major pharmacy chains and government medical outlets will remain operational, the strike highlights significant tensions within the industry that could impact access to medications nationwide. The All India Organisation…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus Lifesciences Q4FY26 net profit rises 9%

Chemists strike on May 20: Reasons behind today’s all-India strike

Chemists strike on May 20: Reasons behind today’s all-India strike

AbbVie loses patent plea for Hep C drug

AbbVie loses patent plea for Hep C drug

GSK’s Calpol a well-known trademark: High Court

GSK’s Calpol a well-known trademark: High Court

3 arrested for allegedly posing as doctors using forged MBBS degrees

3 arrested for allegedly posing as doctors using forged MBBS degrees

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures